TD Cowen began coverage on shares of Clorox (NYSE:CLX – Free Report) in a report published on Tuesday, Marketbeat Ratings reports. The brokerage issued a sell rating and a $122.00 target price on the stock.
Several other equities research analysts have also issued reports on the company. Evercore ISI reduced their price target on Clorox from $145.00 to $142.00 and set an underperform rating for the company in a report on Wednesday, May 1st. Wells Fargo & Company cut their price objective on Clorox from $135.00 to $130.00 and set an underweight rating on the stock in a research note on Wednesday, July 10th. Morgan Stanley reaffirmed an equal weight rating and issued a $160.00 price target on shares of Clorox in a research report on Tuesday, March 26th. BNP Paribas initiated coverage on Clorox in a research report on Monday, June 24th. They issued an underperform rating and a $130.00 price target on the stock. Finally, DA Davidson reaffirmed a neutral rating and issued a $162.00 price target on shares of Clorox in a research report on Wednesday, April 17th. Six research analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $142.13.
Read Our Latest Research Report on CLX
Clorox Trading Up 0.9 %
Clorox (NYSE:CLX – Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.38. Clorox had a return on equity of 302.49% and a net margin of 3.33%. The firm had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same period last year, the company posted $1.51 EPS. The business’s quarterly revenue was down 5.3% compared to the same quarter last year. Analysts expect that Clorox will post 5.91 earnings per share for the current year.
Institutional Trading of Clorox
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Venturi Wealth Management LLC increased its position in Clorox by 308.5% in the first quarter. Venturi Wealth Management LLC now owns 192 shares of the company’s stock worth $29,000 after purchasing an additional 145 shares during the period. Northwest Financial Advisors bought a new position in shares of Clorox during the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. bought a new position in shares of Clorox during the 4th quarter valued at about $29,000. First United Bank & Trust bought a new position in shares of Clorox during the 4th quarter valued at about $31,000. Finally, GoalVest Advisory LLC bought a new position in shares of Clorox during the 1st quarter valued at about $31,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Further Reading
- Five stocks we like better than Clorox
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is an Earnings Surprise?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.